- Home
- SBR vs SVRA Comparison
SBR vs SVRA Comparison
Compare SBR & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SBR | SVRA |
|---|---|---|
| Founded | 1982 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | N/A | 2009 |
Fundamental Metrics
Financial Performance| Metric | SBR | SVRA |
|---|---|---|
| Price | $73.04 | $6.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $7.33 |
| AVG Volume (30 Days) | 25.7K | ★ 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 6.69% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.77 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $58.25 | $1.89 |
| 52 Week High | $84.39 | $7.01 |
Technical Indicators
Market Signals| Indicator | SBR | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 66.85 | 57.55 |
| Support Level | $65.25 | $5.86 |
| Resistance Level | $79.86 | $6.06 |
| Average True Range (ATR) | 1.44 | 0.36 |
| MACD | 0.38 | 0.07 |
| Stochastic Oscillator | 90.81 | 86.67 |
Price Performance
Historical ComparisonAbout SBR Sabine Royalty Trust
Sabine Royalty Trust is an express trust which is formed to receive Sabine Corporation's royalty and mineral interests, including landowner's royalties, overriding royalty interests, minerals production payments and any other similar, non-participatory interests, in certain Royalty Properties. The trusts producing and proved undeveloped oil and gas royalty properties are located in Florida, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.